1Bull BS,Korpman RA,Huse WM,et al.Heparin therapy during extracorporeal circulation: problems inherent in existing heparin protocols[].Journal of Thoracic and Cardiovascular Surgery.1975 被引量：1
2Gravlee GP,Rogers AT,Dudas LM,et al.Heparin management protocol for cardiopulmonary bypass influences postoperative heparinrebound but not bleeding[].Anesthesiology.1992 被引量：1
3Gillinov AM,Redmond JM,Winklestein JA,et al.Complement and neutrophil activation during cardiopulmonary bypass: a study in the complement-deficient dog[].The Annals of Thoracic Surgery.1994 被引量：1
4Mochizuki T,Olson PJ,Szlam F,et al.Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass[].Anesthesia and Analgesia.1998 被引量：1
5Gravlee GP,Case LD,Angert KC,et al.Variability of the activated coagulation time[].Anesthesia and Analgesia.1988 被引量：1
6Kirklin JK,Chenoweth DE,Naftel DC,et al.Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state[].The Annals of Thoracic Surgery.1986 被引量：1
7Gravlee GP,Haddon WS,Rothberger HK,et al.Heparin dosing and monitoring for cardiopulmonary[].Journal of Thoracic and Cardiovascular Surgery.1990 被引量：1
8John LCH,Rees GM,Kovacs IB,et al.Inhibition of platelet function by heparin[].Journal of Thoracic and Cardiovascular Surgery.1993 被引量：1
3Vazquez-Calatayud M, Portillo MC. Comparison between saline solution and heparin in arterial catheter patency in intensive care units: a systematic review [J]. Enferm Clin,2010,20(3) :165. 被引量：1
